Transcatheter Heart Valve Replacement Market Size By Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Repair and Replacement, Transcatheter Pulmonary Valve Replacement), By Surgical Approach (Transfemoral Approach, Transapical Approach), By Application (Aortic Valvular Heart Disease {Aortic Valve Stenosis, Aortic Valve Regurgitation}, Mitral Valvular Heart Disease {Mitr

Transcatheter Heart Valve Replacement Market Size By Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Repair and Replacement, Transcatheter Pulmonary Valve Replacement), By Surgical Approach (Transfemoral Approach, Transapical Approach), By Application (Aortic Valvular Heart Disease {Aortic Valve Stenosis, Aortic Valve Regurgitation}, Mitral Valvular Heart Disease {Mitr

Transcatheter Heart Valve Replacement Market Size

Transcatheter Heart Valve Replacement Market size valued at over USD 6.2 billion in 2019 and is expected to witness 17.6% CAGR between 2020 and 2026.
 

Rise in incidences of valvular heart diseases across the globe along with increasing demand for less invasive procedures is propelling the industry growth. Growing geriatric population suffering from heart valve diseases is leading to increase in valve replacement surgeries. Moreover, increasing technological advancements in surgical procedures is augmenting the transcatheter heart valve replacement market demand. Furthermore, favorable reimbursement scenario and growing interest of manufacturers is fostering the market revenue.
 

The COVID?19 pandemic has imposed burden on healthcare systems and intensive care unit (ICU) capacity that has led to the suspension of several procedures, including transcatheter aortic valve replacement (TAVR). The postponement of these procedures is associated with irreversible cardiac deterioration of patients or sudden cardiac death and is affecting patients suffering from severe aortic valve stenosis. Thus, the American College of Cardiology (ACC) and Society of Cardiac Angiography and Interventions (SCAI) have established guidelines regarding considerations for patients referred for structural heart disease intervention during the COVID?19 pandemic addressing when to perform TAVR for severe symptomatic aortic stenosis. As a result, even with emergence of second wave of COVID-19, transcatheter heart valve industry will perform strongly in the coming duration.
 

Increasing prevalence of valvular disease in developing regions of Asia Pacific will drive the transcatheter heart valve replacement market growth. Aortic valvular stenosis or regurgitation caused by rheumatic heart disease or infective endocarditis is becoming prevalent at a rapid pace in developing countries of Asia Pacific. In addition, a major proportion of population in Asia Pacific suffering from rheumatic aortic stenosis comprises of young patients and is recommended to undergo transcatheter valve replacement. As a result, there is an increased demand for transcatheter heart valve replacement products in the region.
 

Transcatheter Heart Valve Replacement Market Analysis

Transcatheter mitral valve repair & replacement segment is poised to expand at 23.6% CAGR through 2026 owing to the increasing incidences of mitral regurgitation across the globe. Mitral regurgitation is the most prevalent abnormality worldwide and its prevalence is increasing in the geriatric population. According to a study by the National Center for Biotechnology Information (NCBI), approximately 1.3 million adults in the U.S. currently suffer from mitral regurgitation. Therefore, transcatheter mitral valve replacement (TMVR) has emerged as an alternative therapeutic option for the treatment of mitral regurgitation in patients with prohibitive or high surgical risk and is driving the demand for transcatheter mitral valves. Moreover, the growing incidences of ischemic functional secondary mitral regurgitation and degenerative primary mitral regurgitation is further uplifting the demand for transcatheter mitral valves.
 

Transapical approach segment is anticipated to register 18% growth rate during the forecast timeframe propelled by the antegrade approach and provision of easy wiring with excellent controllability. The transapical approach enables easier accessibility to the aortic valve with easier controllability. Therefore, this approach is widely used in transcatheter aortic valve implementation (TAVI) and transcatheter mitral valve replacement procedures. In addition, transapical approach is easier to perform, maintains proximity to the target and enables a controlled implantation.
 

Hospitals segment size in the transcatheter heart valve replacement market was more than USD 3,652 million in 2019 due to the reimbursement received by the hospitals for valve replacement procedures as these procedures are expensive. Moreover, presence of skilled surgeons in hospital setting and availability of technologically advanced equipment and tools utilized in heart valve replacement procedures is augmenting the number of people opting for transcatheter heart valve replacement in hospitals.
 

Aortic valvular heart disease segment revenue was around USD 4,818 million in 2019 on account of rising incidences of aortic valvular heart disease. Moreover, growing geriatric population is also contributing to the increasing prevalence of aortic valvular heart disease. This is because the people over the age of 70 years are prone to aortic stenosis. In addition, around 15% of the patients with 40 years or above age are prone to suffer from aortic stenosis due to bicuspid aortic valve. Aortic stenosis is the second most common valvular lesion in the U.S.
 

U.S. dominated the North America transcatheter heart valve replacement market and held largest revenue share of around 88% in 2019 attributed to the growing prevalence of heart valve disorders in the U.S. According to a published article, approximately, 5 million people in the U.S. are diagnosed with heart valve disorder every year. Therefore, more than 80,000 aortic valve replacement (AVR) procedures are performed each year in the country. As a result, the demand for transcatheter heart valves in the U.S. is consistent. Favorable reimbursement scenario by the Centers for Medicare & Mediclaim pertaining to transcatheter heart valve replacement procedures is additionally fueling the number of people undergoing valve replacement. Moreover, growing number of transcatheter aortic valve replacement centers (TAVR) centers in the U.S. is uplifting the adoption of AVR procedures in the country.
 

Germany transcatheter heart valve replacement market value in 2019 was over USD 383 million due to the improved healthcare infrastructure in the country and rising prevalence of aortic stenosis in geriatric population. According to a published report, more than 25,000 TAVR procedures are currently performed in Germany. The country has been leading in the clinical adoption of transcatheter aortic valve implantation (TAVI) and introduced TAVR routinely is some selected centers in 2006. Moreover, German Aortic Valve Registry, established in 2011, is engaged in providing data for reimbursement. Moreover, presence of highly skilled interdisciplinary team of heart specialists in the country is contributing to an increased number of transcatheter heart valve replacement procedures in the country.
 

Transcatheter Heart Valve Replacement Market Share

Some of the major players operating in the transcatheter heart valve replacement industry include

• 4C Medical Technologies
• Abbott
• Boston Scientific
• Edwards Lifesciences
• HighLife Medical
• JC Medical
• LivaNova
• Medtronic plc
• Neovasc

These major market players are engaged in undertaking several strategic mergers, acquisitions, collaborations and partnerships in order to maintain a competitive edge over their peers. These players are also engaged in making investments that enables these players in capturing maximum revenue share.
 

Recent industry developments

• In April 2020, Abbott announced receiving CE Mark approval for TriClip Transcatheter Tricuspid Valve Repair System for use in Europe and other countries that consider CE Mark as a non-surgical treatment for people. The strategic move will assist the company in enhancing their product portfolio and expanding their geographical presence.
   
• In September 2019, Medtronic plc announced the launch of Next-Generation Evolut PRO + TAVR System for treatment of symptomatic severe aortic stenosis patients. The strategic move assisted the company in enhancing their product portfolio and expanding their customer base.
   

The transcatheter heart valve replacement market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD and in terms of Units from 2015 to 2026, for the following segments

Click here to Buy Section of this Report

 

Market, By Product

• Transcatheter Aortic Valve Replacement
• Transcatheter Mitral Valve Repair and Replacement
• Transcatheter Pulmonary Valve Replacement

Market, By Surgical Approach

• Transfemoral Approach
• Transapical Approach
• Others

Market, By Application

• Aortic Valvular Heart Disease
  • Aortic Valve Stenosis
  • Aortic Valve Regurgitation
• Mitral Valvular Heart Disease
  • Mitral Valve Stenosis
  • Mitral Valve Regurgitation
• Pulmonary Valvular Heart Disease

Market, By End-Use

• Hospitals
• Cath labs

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel